AstraZeneca: Imfinzi a success in lung cancer
(CercleFinance.com) - AstraZeneca announced on Thursday that one of its flagship immunotherapies, Imfinzi, has succeeded in improving the survival of patients with a form of lung cancer whose tumour is operable.
The phase III trial found that treatment with Imfinzi before and after surgery "significantly" increased event-free survival (i.e. without recurrence or progression of the disease) in patients with non-small cell cancer.
Patients with non-small cell cancer face unacceptably high rates of disease recurrence, despite treatment with chemotherapy and surgery, AstraZeneca said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The phase III trial found that treatment with Imfinzi before and after surgery "significantly" increased event-free survival (i.e. without recurrence or progression of the disease) in patients with non-small cell cancer.
Patients with non-small cell cancer face unacceptably high rates of disease recurrence, despite treatment with chemotherapy and surgery, AstraZeneca said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.